Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT

CMG901 FOR THE TREATMENT OF GASTRIC CANCER AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA WAS GRANTED THE ORPHAN-DRUG DESIGNATION BY THE FOOD AND DRUG ADMINISTRATION OF THE UNITED STATES

This announcement is made by Keymed Biosciences Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company is pleased to announce that its new drug candidate CMG901 (the "**Claudin 18.2 antibody drug conjugates**") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by the Food and Drug Administration of the United States (the "**FDA**") recently. Previously, in March, 2021, we received the clinical trial application approval of CMG901 from the FDA for the clinical trial in gastric cancer and gastroesophageal junction adenocarcinoma in the United States.

ABOUT CMG901

CMG901 is a Claudin 18.2-targeting antibody drug conjugates comprising of a Claudin 18.2-specific antibody, a cleavable linker and a toxic payload, monomethyl auristatin E (MMAE). It is the first Claudin 18.2 antibody drug conjugates to have received both clinical trial application approval in China and the United States. The high specificity of the Claudin 18.2 is expressed in gastric cancer, pancreatic cancer and other solid tumors, which makes it an ideal tumor target for therapeutic development.

We are currently in the dose-escalation stage of CMG901 in patients with solid tumors to evaluate the safety and tolerability of CMG901. We expect to initiate the dose-expansion stage in China in early second quarter of 2022.

IMPACT OF THE DESIGNATION ON THE COMPANY AND RISK WARNING

The Orphan-drug Designation obtained from the FDA of the United States will help CMG901 enjoy certain policy supports for the follow-up research and development, registration and commercialization for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma in the United States, including but not limited to (1) tax credit for clinical trial expenses; (2) waiver of application fees for new drugs; and (3) 7 years of market exclusivity without being affected by patent.

If other identical drugs for the same indication are approved for launching before the FDA of the United States approves the launch of CMG901 for the treatment of indications such as gastric cancer and gastroesophageal junction adenocarcinoma, the further justification of clinical superiority of CMG901 is required, otherwise it will be deprived of the policy support in enjoying market exclusivity as an orphan-drug.

This announcement is made by the Company on a voluntary basis to provide information to the shareholders and potential investors of the Company. There is no assurance that the Company will ultimately develop, launch and/or commercialize the product successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, April 11, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.